The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure

NCT02284230 · Withdrawn

Last updated 2026-05-28

This clinical trial tests the effect of the medication liraglutide on blood sugar levels in adults with both prediabetes and chronic kidney failure.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Who can join Ages 18–85 · all sexes

Timeline Started 2014-12 · est. completion 2015-08

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02284230 ↗

Description as written by the study sponsor.

The present study will examine the effects of liraglutide treatment during 26 weeks on several cardiovascular risk factors in patients with prediabetes and end-stage renal disease (ESRD). The primary objective is to determine the efficacy of the treatment on glucose tolerance evaluated during a 3h 75g-oral glucose tolerance test (OGTT). Secondary objectives include various clinical and biochemical cardiovascular and safety parameters. We hypothesise that treatment with liraglutide can improve glucose tolerance in prediabetic patients with ESRD by normalizing plasma glucose excursions during an OGTT and ameliorate other cardiovascular risk factors.

Treatments tested

Liraglutide also known as Victoza Drug
Placebo Drug

Main thing measured	Plasma glucose during oral glucose tolerance test at week 26
Sponsor	Bo Feldt-Rasmussen
Conditions studied	Kidney Failure, Chronic, Prediabetic State
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02284230 ↗